lodelcizumab

Lodelcizumab (also known as LGT209) is a fully human monoclonal antibody that was developed to treat hypercholesterolemia. It functions by targeting and inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, lodelcizumab prevents the protein from mediating the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. This inhibition leads to an increased density of LDLRs, facilitating the clearance of low-density lipoprotein cholesterol (LDL-C) from the circulation. Developed by Novartis, the drug reached Phase 2 clinical trials, where it was evaluated as both a monotherapy and an add-on to statin treatment. However, Novartis discontinued its development in late 2014 as part of a strategic portfolio prioritization.

Other names

LGT209LGT-209LGT 209